Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Pharmacotherapy

Disparate bedfellows in a lasting drug union?

Nature Reviews Endocrinology volume 9, pages 135–136 (2013)Cite this article

Subjects

Finan and colleagues report a new approach to combination therapy for the metabolic syndrome—glucagon-like peptide 1 and oestradiol linked chemically to produce a fusion molecule. Treatment with this fusion molecule results in an improvement of the metabolic profile of mice with diet-induced obesity with a minimum of oestrogenic adverse effects.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Finan, B. et al. Targeted estrogen delivery reverses the metabolic syndrome. Nat. Med. 18, 1847–1856 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Muller, T. D. et al. Restoration of leptin responsiveness in diet-induced obese mice using an optimized leptin analog in combination with exendin-4 or FGF21. J. Pept. Sci. 18, 383–393 (2012).

    Article  PubMed  Google Scholar 

  3. Amori, R. E., Lau, J. & Pittas, A. G. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 298, 194–206 (2007).

    Article  CAS  Google Scholar 

  4. Le May, C. et al. Estrogens protect pancreatic beta-cells from apoptosis and prevent insulin-deficient diabetes mellitus in mice. Proc. Natl Acad. Sci. USA 103, 9232–9237 (2006).

    Article  CAS  PubMed  Google Scholar 

  5. Jones, M. E. et al. Aromatase-deficient (ArKO) mice have a phenotype of increased adiposity. Proc. Natl Acad. Sci. USA 97, 12735–12740 (2000).

    Article  CAS  PubMed  Google Scholar 

  6. Xu, Y. et al. Distinct hypothalamic neurons mediate estrogenic effects on energy homeostasis and reproduction Cell Metab. 14, 453–465 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Dunphy, J. L., Taylor, R. G. & Fuller, P. J. Tissue distribution of rat glucagon receptor and GLP-1 receptor gene expression. Mol. Cell. Endocrinol. 141, 179–186 (1998).

    Article  CAS  Google Scholar 

  8. Gao, Q. & Horvath T. L. Cross-talk between estrogen and leptin signalling in the hypothalamus. Am. J. Physiol. Endocrinol. Metab. 294, E817–E826 (2008).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Prince Henry's Institute of Medical Research, Level 4 Block E, Monash Medical Centre, Clayton, 3168, VIC, Australia

    Evan R. Simpson & Peter J. Fuller

Authors
  1. Evan R. Simpson
    View author publications

    Search author on:PubMed Google Scholar

  2. Peter J. Fuller
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Evan R. Simpson.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Simpson, E., Fuller, P. Disparate bedfellows in a lasting drug union?. Nat Rev Endocrinol 9, 135–136 (2013). https://doi.org/10.1038/nrendo.2013.19

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrendo.2013.19

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing